None listed
Conditions
Interventions
Drug : This clinical trial was designed with a single organ, random assignment, comparator comparison, parallel design, and open study. For patients who have performed coronary artery interventions, p
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria 1) Patients with coronary artery disease who were 19 years of age or older and needed coronary angiography 2) Patients who needed percutaneous coronary intervention for coronary artery disease 3) Intermediate coronary artery stenosis (diameter stenosis =30% to =60% by visual estimation, diameter =2.0 mm to =4.0 mm, de novo lesion in native coronary artery) in which intravascular ultrasound could be feasible 4) Baseline serum LDL-C = 70mg/dL 5) Patients who gave written informed consent
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Cardiogenic shock 2) Heart failure with symptoms of New York Heart Association class III/IV or left ventricular ejection fraction 3 times of normal within limit) 7) Patients with difficulty in assessing intravascular ultrasonography for the following reasons: severe calcification, severe tortuous vessels, total occlusion 8) Patients who can not receive adequate antiplatelet therapy 9) Thrombocytopenia (platelet count < 70x109/L)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent atheroma volume of intermediate in the vascular wall of the mild and intermediate stenosis lesion after 12months Lipid-lowering Drug | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent atheroma volume in the vascular wall;Lipid core burden index;Absolute and percent changes in the lipid, glycemic and inflammatory profiles | — |
Countries
Korea, Republic of
Contacts
Public ContactKang Woong chol
Gachon University Gil Medical Center
Outcome results
None listed